News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
519,646 Results
Type
Article (44335)
Company Profile (135)
Press Release (475176)
Section
Business (144740)
Career Advice (2387)
Deals (27890)
Drug Delivery (113)
Drug Development (67818)
Employer Resources (148)
FDA (15560)
Job Trends (11927)
News (263263)
Policy (29565)
Tag
Academia (2282)
Alliances (35802)
Alzheimer's disease (1310)
Approvals (15489)
Artificial intelligence (133)
Bankruptcy (300)
Best Places to Work (9151)
Breast cancer (175)
Cancer (1298)
Cardiovascular disease (111)
Career advice (1993)
CAR-T (94)
Cell therapy (275)
Clinical research (54131)
Collaboration (414)
Compensation (261)
COVID-19 (2555)
C-suite (100)
Data (1281)
Diabetes (173)
Diagnostics (5113)
Drug pricing (104)
Earnings (57201)
Employer resources (136)
Events (75143)
Executive appointments (344)
FDA (16233)
Funding (351)
Gene therapy (204)
GLP-1 (669)
Government (3802)
Healthcare (14715)
Infectious disease (2650)
Inflammatory bowel disease (105)
Interviews (445)
IPO (13834)
Job creations (3153)
Job search strategy (1661)
Layoffs (456)
Legal (6909)
Lung cancer (192)
Lymphoma (98)
Manufacturing (199)
Medical device (11082)
Medtech (11085)
Mergers & acquisitions (14201)
Metabolic disorders (494)
Neuroscience (1626)
NextGen Class of 2024 (4970)
Non-profit (3158)
Northern California (1555)
Obesity (288)
Opinion (193)
Patents (116)
People (41966)
Phase I (16161)
Phase II (23432)
Phase III (19281)
Pipeline (512)
Postmarket research (2202)
Preclinical (6536)
Radiopharmaceuticals (202)
Rare diseases (265)
Real estate (4247)
Regulatory (20360)
Research institute (2050)
Resumes & cover letters (401)
Southern California (1298)
Startups (2735)
United States (13293)
Vaccines (634)
Weight loss (231)
Date
Today (34)
Last 7 days (566)
Last 30 days (2142)
Last 365 days (31361)
2024 (31225)
2023 (34982)
2022 (45057)
2021 (48498)
2020 (45511)
2019 (36210)
2018 (27396)
2017 (27804)
2016 (25803)
2015 (27973)
2014 (21774)
2013 (17791)
2012 (18963)
2011 (19381)
2010 (17504)
Location
Africa (667)
Arizona (139)
Asia (30619)
Australia (5365)
California (3397)
Canada (1081)
China (234)
Colorado (152)
Connecticut (176)
Europe (74313)
Florida (492)
Georgia (115)
Illinois (305)
Indiana (174)
Maryland (585)
Massachusetts (2642)
Michigan (133)
Minnesota (234)
New Jersey (988)
New York (936)
North Carolina (677)
Northern California (1555)
Ohio (116)
Pennsylvania (805)
South America (1032)
Southern California (1298)
Texas (477)
Washington State (358)
519,646 Results for "stalicla s a".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Drug Development
STALICLA initiates U.S. Phase 3 enabling DDI study of STP7 (Mavoglurant) to treat cocaine use disorder
STALICLA SA announces the First Patient First Visit for the company’s drug-drug interaction study of STP7, an mGluR5 negative allosteric modulator, licensed to STALICLA by Novartis.
May 2, 2024
·
2 min read
Business
STALICLA Appoints Dr. Thomas Blaettler, MD
STALICLA SA announced the appointment of Thomas Blaettler, to the position of Chief Medical Officer.
April 11, 2024
·
3 min read
Drug Development
STALICLA publishes pioneering phase 1b data on precision treatment for autism spectrum disorder in Biomedicines
STALICLA SA announced the publication of a landmark phase 1b study with STP1, a novel combination therapy tailored for the treatment of a clinically and biologically defined subgroup of patients with autism spectrum disorder, named ASD Phenotype 1.
June 27, 2024
·
3 min read
Stalicla Secures $17.4 Million in Series B Financing to Propel Precision Neuro Advancements
Stalicla SA announces the successful completion of the first closing of its Series B financing round, securing $17.4 million.
January 16, 2024
·
2 min read
Business
STALICLA appoints Dr. Purnanand Sarma, PhD, as Chair of the Board of Directors
July 10, 2024
·
2 min read
Business
STALICLA and Firefly Neuroscience enter Partnership Agreement for the Development of Electroencephalogram (EEG) as a Biomarker for Subgroups of Patients with ASD
STALICLA and Firefly Neuroscience today announced a partnership to further validate EEG-based biomarkers in biologically enriched subgroups of patients with Autism Spectrum Disorder (ASD).
March 27, 2023
·
5 min read
STALICLA signs exclusive in-licensing agreement for late-stage clinical neuropsychiatric and neurodevelopmental disorder treatment
STALICLA SA announced that it has entered into an exclusive in-licensing agreement with Novartis to develop mavoglurant as a treatment for substance-use disorder and neurodevelopmental disorders.
January 9, 2023
·
3 min read
STALICLA to in-license SFX-01 from Evgen for neurodevelopment disorder indications
STALICLA SA today announced the worldwide in-licensing of SFX-01 from Evgen Pharma plc (Evgen) in neurodevelopmental disorders and schizophrenia, with a first indication for a biologically-characterized subgroup of patients with Autism Spectrum Disorder (ASD).
October 10, 2022
·
4 min read
Drug Development
STALICLA signs Cooperative Research and Development Agreement (CRADA) with US National Institute on Drug Abuse (NIDA) to cover Phase 3 development of mavoglurant in cocaine use disorder
STALICLA SA, a clinical stage biotech advancing the first precision neurobiology platform (DEPI) for patients with neurodevelopmental and neuropsychiatric disorders, today announced that it has entered into a Cooperative Research and Development Agreement (CRADA) with the US National Institute on Drug Abuse (NIDA), part of the US National Institutes of Health (NIH).
March 8, 2023
·
3 min read
Podcast
BridgeBio’s ATTR-CM Approval, Cassava’s Alzheimer’s Failure, Trump’s Cabinet Picks, More
BridgeBio’s Attruby wins approval for transthyretin amyloid cardiomyopathy while the FDA accepts Alnylam’s application for Amvuttra in the indication; Cassava’s controversial Alzheimer’s drug flunks Phase III; Amgen’s MariTide fails to impress investors, Donald Trump’s controversial nominations continue.
November 27, 2024
·
1 min read
·
Heather McKenzie
1 of 51,965
Next